Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EU307 in Advanced Hepatocellular Carcinoma
NCT05783570Phase 1Recruiting
- Sponsor
- Eutilex Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EU307 in hepatocellular carcinoma (HCC), sponsored by Eutilex Co., Ltd. Primary endpoints: Adverse Events up to 6 months, Production of replication competent lentiviruses up to 6 months and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
EU307
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05783570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783570.